Health and Healthcare
IPO Withdrawal: ChemoCentryx (GSK)
Published:
Last Updated:
On Friday, ChemoCentryx Inc. filed to withdraw its pending registration for an IPO of up to $57.5 million. The market conditions of today are cited as the reasoning. The Mountain View, California-based company said in its filing, "At this time, due to current public market conditions, the Company has determined not to proceed with the initial public offering contemplated…"
ChemoCentryx is an emerging drug developer for autoimmune andinflammatory diseases, as well as oncology. Credit Suisse was the leadunderwriter and the company has raised $50 million in venture backingfrom GlaxoSmithKline (NYSE: GSK) to a total amount raised of what looksto be more than $150 million from Glaxo and other venture investors.
This form "RW’ for withdrawal may have been no surprise to most as the initial filing came on November 9, 2007.
JON C. OGG
NOVEMBER 17, 2008
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
